Debiopharm

From Wikipedia, the free encyclopedia
Debiopharm Group
TypeSociété Anonyme
IndustryBiopharmaceutical
FoundedLausanne, Switzerland (1979)
FounderDr Rolland-Yves Mauvernay (1922-2017)
HeadquartersLausanne, Switzerland
Area served
Worldwide
Key people
  • Thierry Mauvernay (President)
  • Bertrand Ducrey (CEO Debiopharm International SA)
  • Cédric Sager (CEO Debiopharm Research & Manufacturing SA)
  • Valérie Calvayrac (CEO Debiopharm Investment SA)
Products
RevenueUS$ 25 billion
Ownerfamily-owned
Number of employees
420
Websitewww.debiopharm.com

Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies active in drug development and manufacturing of proprietary drugs, diagnostics, and investments,[1] headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.[2]

Subsidiaries[]

The group works through its subsidiaries:[3]

  • Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;[4]
  • Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;[5]
  • Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and[6]
  • Debiopharm Diagnostics SA, which invests in diagnostics companies.[7]

As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.[8]

In 2017, Debiopharm acquired a phase 2 drug candidate from ImmunoGen that intends to target Non-Hodgkin lymphoma.[9]

References[]

  1. ^ Group, Debiopharm. "Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)". www.prnewswire.com. Retrieved 2020-04-10.
  2. ^ Bloomberg profile: Debiopharm Group. Page accessed May 12, 2016
  3. ^ Frost & Sullivan Nov 25 2010 Movers & Shakers Interview with Maurice Wagner, Debiopharm Group
  4. ^ Bloomberg profile: Debiopharm International. Page accessed May 12, 2016
  5. ^ Bernard Tappy for In Vivo Magazine. 2013 Debiopharm Research and Manufacturing SA.
  6. ^ Swiss Private Equity & Corporate Finance Association Debiopharm Investment SA Page accessed May 12, 2016
  7. ^ Bloomberg profile: Debiopharm Diagnostics. Page accessed May 12, 2016
  8. ^ "Triptorelin". drugs.com. Retrieved 11 November 2016.
  9. ^ Taylor, Nick (24 May 2017). "Debiopharm buys ImmunoGen ADC to grow cancer pipeline". Fierce Biotech. Retrieved 23 June 2018.

External links[]

Coordinates: 46°30′54″N 6°38′28″E / 46.51500°N 6.64111°E / 46.51500; 6.64111

Retrieved from ""